Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 9/2017

01-09-2017 | Epilepsy (CW Bazil, Section Editor)

Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches

Author: Jeffrey M. Politsky

Published in: Current Neurology and Neuroscience Reports | Issue 9/2017

Login to get access

Abstract

Purpose of Review

The relationship of brain tumors and seizures remains poorly understood. This article is an overview of the epidemiology, etiology, and diagnostic and treatment approaches of tumor-related epilepsy primarily with regard to glial-based tumors, the most commonly considered brain tumor in this field.

Recent Findings

Over the past many years, several novel etiologic mechanisms to explain how tumors induce seizures have been developed, which this article reviews, including the roles of glutamate-induced excitotoxicity, matrix metalloproteinases, isocitrate dehydrogenase, methylguanine methyltransferase, and functional network connectivity. As well, diagnostic and treatment approaches vary considerably. This article summarizes the evidence and provides the rationale for a reconsideration of how we deliver pre-operative, peri-operative, and post-operative care to these patients.

Summary

Patients with brain tumors and epilepsy are a very challenging subgroup of patients, which necessitates not just a thorough understanding of the current principles regarding tumor-related epilepsy but also the development of collaborative research to advance our knowledge even further, and a concerted effort to develop a standardized, multi-disciplinary clinical approach to improve the care of these patients.
Literature
1.
Cascino GD. Epilepsy and brain tumors: implications for treatment. Epilepsia. 1990;31(suppl):S37–44.PubMedCrossRef
2.
Pace A, Bove L, Innocenti P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exper Clin Can Res. 1998;17:479–82.
3.
Lynam L, Lyons M, Drzkowski J, Sirven J, Noe K, Zimmerman R, et al. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg. 2007;109:634–8.
4.
Lote K, Stenwig AE, Skullerud K, Hirschber H. Prevalence and prognositic significance of epilepsy in patients with gliomas. Eur J Cancer. 1998;34:98–102.PubMedCrossRef
5.
Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442–8.PubMedCrossRef
6.
Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, et al., The Nice Brain Tumor Study Group. Long-term outcome of oligodendrogliomas. Neurology. 2004;62:1783–7.PubMedCrossRef
7.
8.
Fernandez-Concepcion O, Gomez-Garcia A, Bonet-Gorvea M. Cerebral tumors as a cause of late onset epilepsy. Rev Neurol. 1996;29:1142–6.
9.
Penfield W, Erickson TI. Relation of intracranial tumors and symptomatic epilepsy. Arch Neurol Psych. 1940;44:300–15.CrossRef
10.
Van Breemen M, Rijsman R, Taphoorn M, Walchenbach R, Zwinkels H, Vecht C. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256:1519–26.PubMedCrossRef
11.
Shady JA, Black PM, Kupsky WJ, et al. Seizures in children with supratentorial astroglial neoplasms. Pediatr Neurosurg. 1994;21:23–30.PubMedCrossRef
12.
• Pallud J, Audreau E, Bionski M, Sanai N, Bauchet L, Fontaine D, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain. 2014;137:449–62. This is a retrospective review that examines the natural course of diffuse low-grade glioma and seizures. PubMedCrossRef
13.
Shamji M, Fric-Shamji E, Benoit B. Brain tumors and epilepsy: pathophysiology of peritumoral change. Neurosurg Rev. 2009;32:275–85.PubMedCrossRef
14.
Wolf H, Roos D, Blumcke I, Pietsch T, Wiestler O. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol (Berl). 1996;91:376–84.CrossRef
15.
Kohling R, Senner V, Paulus W, Speckmann E. Epileptiform activity preferentially arises outside tumor invasion zone in glioma xeno-transplants. Neurobiol Dis. 2006;22:64–75.PubMedCrossRef
16.
Rothman S. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J Neurosci. 1985;5:1483–9.PubMed
17.
Choi D. Ionic dependence of glutamate neurotoxicity. J Neurosci. 1987;7:369–79.PubMed
18.
Meldrum B. The role of glutamate in epilepsy and other cns disorders. Neurol. 1994;44(Suppl 8):S14–23.
19.
Rothstein J, Dykes-Hoberg M, Pardo C, Bristol L, Jin L, Kuncl R, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675–86.PubMedCrossRef
20.
Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter glt-1. Science. 1997;276:1702.CrossRef
21.
Chen Y, Swanson R. The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J Neurochem. 2003;84:1332–9.PubMedCrossRef
22.
Lewerenz J, Hewett S, Huang Y, Lambros M, Gout P, Kalivas P, et al. The cysteine/glutamate antiporter system xc- in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal. 2013;18:522–55.PubMedPubMedCentralCrossRef
23.
24.
Wang J, Erickson J, Fuji R, Ramachandran S, Gao P, Dinavah R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18:207–19.PubMedPubMedCentralCrossRef
25.
Hensely C, Wasti A, DeBeradinis R. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123:3678–84.CrossRef
26.
Rosati A, Marconi S, Pollo B, Tomassini A, Lovato L, Maderna E, et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neuro-Oncol. 2009;93:319–24.CrossRef
27.
Rosati A, Polari P, Todeschini A, Cominelli M, Medicina D, Cenzato M, et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival newly diagnosed glioblastoma multiforme. Neuro-Oncology. 2013;15:618–25.PubMedPubMedCentralCrossRef
28.
Ye Z, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 1999;59:4383–91.PubMed
29.
30.
Marcus H, Carpenter K, Prie S, Hutchinson P. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors, and cytokines. J Neuro-Oncol. 2010;97:11–23.CrossRef
31.
Yuen T, Morokoff A, Bjorksten A, D’Abaco G, Paradiso L, Finch S, et al. Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology. 2012;79:883–9.PubMedCrossRef
32.
• Buckingham S, Campbell S, Haas B, Montana V, Robel S, Ogunrinu T, et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2012;17:1269–74. This paper from Sontheimer’s lab discusses the pathophysiologic effects of glutamate release from gliomas and the role of glutamate in tumor-related epilepsy.
33.
34.
Phillips H, Kharbanda S, Chen R, Forrest W, Soriano R, Wu T, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73.PubMedCrossRef
35.
Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilderson M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, and NF1. Cancer Cell. 2010;17:510–22.PubMedPubMedCentralCrossRef
36.
Berntsson S, Malmer B, Bondy M, Qu M, Smits A. Tumor-associated epilepsy and glioma: are there common genetic pathways? Acta Oncol. 2009;48:955–63.PubMedCrossRef
37.
Thom M, Blumcke I, Aronica E. Long-term epilepsy-associated tumors. Brian Pathol. 2012;22:350–79.CrossRef
38.
Esteller M, Garcia-Foncillas J, Andion E, Goodman S, Hidalgo O, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–4.
39.
Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRef
40.
Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, et al. O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One. 2011;6(2):e17156.PubMedPubMedCentralCrossRef
41.
Zhang K, Wang X, Zhou B, Zhang L. The prognostic value of MGMT promoter methylation in glioblastoma multiforme: a meta-analysis. Familial Cancer. 2013;12:449–58.PubMedCrossRef
42.
Kobow K, Kaspi A, Harikrishnan K, Kiese K, Ziemann M, Khurana I, et al. Deep sequencing reveals increased DNA methylation in chronic rat epilepsy. Acta Neuropathol. 2013a;126:741–56.PubMedPubMedCentralCrossRef
43.
Kobow K, El-Osta A, Blumcke I. The methylation hypothesis of pharmacoresistance in epilepsy. Epilepsia. 2013b;54(Suppl 2):41–7.PubMedCrossRef
44.
Nedivi E, Hervoni D, Naot D, Israell D, Citri Y. Numerous candidate plasticity-related genes revealed by differential cDNA cloning. Nature. 1993;363:718–22.PubMedCrossRef
45.
Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatisky M. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neruons and astrocytes after seizures: evidence or developmental, immediate early gene, and lesion response. J Neurosci. 1997;17:4223–35.PubMed
46.
Wright J, Brown T, Harding J. Inhibition of matrix metalloproteinase-3 and -9 disrupts spatial memory. Neural Plasticity. 2007;2007:article ID 73813.
47.
Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, et al. Matrix metalloproteinase-9 I srequired for hippocampal late-phase long-term potentiation and memory. J Neurosci. 2006;26:1923–34.
48.
Okulski P, Jay T, Jaworski J, Duniec K, Dzwonek J, Konopacki F, et al. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry. 2007;62:359–62.
49.
Wright J & Harding J. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plasticity. 2009;2009:article ID 579382.
50.
• Mizoguchi H, Yamada K, Nabeshima T. matrix metalloproteinases contribute to neuronal dysfunction in animal models of drug dependence, Alzheimer’s disease, and epilepsy. Biochemistry Research International. 2011;2011:article ID 681385. Matrix metalloproteinases is an enzyme family that has critical roles in several normal and disease states, highlighted in this paper.
51.
Koyama R, Yamada M, Fujisawa S, Katoh-Semba R, Matsuki N, Ikegaya Y. Brain-derived neurotrophic factor induces hyperexcitable reentrant circuits in the dentate gyrus. J Neurosci. 2004;24:7215–24.PubMedCrossRef
52.
Wang M, Wang T, Liu S, Yoshida D, Teramoto A. The expressin of matrix metalloptroteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathology. 2003;20:65–72.PubMedCrossRef
53.
Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson W, Quaranta V. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science. 1997;277:225–8.PubMedCrossRef
54.
Dong J, Opresko L, Dempsey P, Lauffenburger D, Coffey R, Wiley H. Metalloproteinase-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor. Proc Natl Acad Sci. 1999;96:6235–40.PubMedPubMedCentralCrossRef
55.
Stettler-Stevenson W. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Investigation. 1999;103:1237–41.CrossRef
56.
McCawley L, Matrisian L. Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol. 2001;13:534–40.PubMedCrossRef
57.
Choe G, Park J, Jouben-Steele L, Kremen T, Liau L, Vinters H, et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002;8:2894–901.
58.
59.
• Lubinas S, D’Abaco G, Moffat B, Gonzales M, Feleppa F, Nowell C, et al. IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Epilepsia. 2014;55:1438–43. This paper highlights the role of IDH1 mutation in tumor-related epilepsy. CrossRef
60.
Kolker S, Pawlak V, Ahlemeyer B, Okun J, Horster F, Mayatepek E, et al. NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur J Neurosci. 2002;16:21–8.PubMedCrossRef
61.
62.
63.
De Groot M, Iyer A, Zurolo E, Anink J, Heimans J, Boison D, et al. Overexpression of ADK in human astrocytic tumors and pertumoral tissue is related to tumor-associated epilepsy. Epilepsia. 2012;53:58–66.
64.
Watts DJ, Strogatz SH. Collective dynamics of ‘small-world’ networks. Nature. 1998;393:440–2.PubMedCrossRef
65.
Stam CJ. Functional connectivity patterns of human magnetoencephalographic recordings: a ‘small-world’ network? Neurosci Lett. 2004;355:25–8.PubMedCrossRef
66.
Salvador R, Suckling J, Schwarzbauer C, Bullmore E. Undirected graphs of frequency-dependent functional connectivity in whole brain networks. Philos Trans R Soc Lond Ser B Biol Sci. 2005;360:937–46.CrossRef
67.
He Y, Chen ZJ, Evans AC. Small-world anatomical networks in the human brain revealed by cortical thickness from MRI. Cereb Cortex. 2007;17:2407–19.PubMedCrossRef
68.
Bartolomei F, Bosma I, Klein M, Baayen JC, Reijneveld JC, Postma TJ, et al. How do brain tumors alter functional connectivity? A magnetoencephalography study. Ann Neurol. 2006a;59:128–38.PubMedCrossRef
69.
Bartolomei F, Bosma I, Klein M, Baayen JC, Reijneveld JC, Postma TJ, et al. Disturbed functional connectivity in brain tumour patients: evaluation by graph analysis of synchronization matrices. Clin Neurophysiol. 2006b;117:2039–49.PubMedCrossRef
70.
Bosma I, Douw L, Bartolomei F, Heimans J, van Dijk B, Postma T, et al. Synchronized brain activity and neurocognitive function in patients with low-grade glioma: a magnetoencephalography study. Neuro-Oncology. 2008;10:734–44.PubMedPubMedCentralCrossRef
71.
Bosma I, Reijneveld J, Klein M, Douw L, van Dijk B, Heimans J, et al. Disturbed functional brain networks and neurocognitive function in lowgrade glioma patients: a graph theoretical analysis of resting-state MEG. Nonlinear Biomed Phys. 2009;3:9.
72.
Douw L, de Groot M, van Dellen E, Heimans JJ, Ronner HE, Stam CJ. Reijneveld JC: ‘functional connectivity’ is a sensitive predictor of epilepsy diagnosis after the first seizure. PLoS One. 2010;5:e10839.PubMedPubMedCentralCrossRef
73.
Horstmann MT, Bialonski S, Noennig N, Mai H, Prusseit J, Wellmer J, et al. State dependent properties of epileptic brain networks: comparative graph-theoretical analyses of simultaneously recorded EEG and MEG. Clin Neurophysiol. 2010;121:172–85.
74.
Liao W, Zhang Z, Pan Z, Mantini D, Ding J, Duan X, et al. Altered functional connectivity and small-world in mesial temporal lobe epilepsy. PLoS One. 2009;5:e8525.
75.
van Dellen E, Douw L, Baayen JC, Heimans JJ, Ponten SC, Vandertop WP, et al. Long-term effects of temporal lobe epilepsy on local neural networks: a graph theoretical analysis of corticography recordings. PLoS One. 2009;4:e8081.PubMedPubMedCentralCrossRef
76.
Douw L, van Dellen E, De Groot M, Heimans J, Klein M, Stam C, et al. Epilepsy is related to theta ban brain connectivity and network topology in brain tumor patients. BMC Neurosci. 2010;11:103.
77.
• Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000;54:1886–93. This sample of sequential publications represents, including meta-analyses, represents independent evaluations of the role of prophylactic anti-seizure drug therapy in brain tumor patients, all with similar conclusions. PubMedCrossRef
78.
Sirven J, Wingerchuk D, Drazkowski J, Lyons M, Zimmerman R. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489–94.PubMedCrossRef
79.
• Tremont-Lukats I, Ratilal B, Armstrong T, Gilbert M. Antiepileptic drugs for preventing seizures in patients with brain tumors. Cochrane Database Syst Rev. 2008;2:CD004424. This sample of sequential publications represents, including meta-analyses, represents independent evaluations of the role of prophylactic anti-seizure drug therapy in brain tumor patients, all with similar conclusions.
80.
Kong X, Guan J, Yang Y, Li Y, Ma W, Wang R. A meta-analysis: do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures? Clin Neurol Neurosurg. 2015;134:98–103.PubMedCrossRef
81.
• Sayegh E, Fakurnejad S, Oh T, Bloch O, Parsa A. Anti-convulsant prophylaxis for brain tumor surgery: determining the current best available evidence. J Neurosurg. 2014;121:1139–47. This sample of sequential publications represents, including meta-analyses, represents independent evaluations of the role of prophylactic anti-seizure drug therapy in brain tumor patients, all with similar conclusions. PubMedCrossRef
82.
Glantz M, Friedberg M, Cole B, et al. Double-blind, randomized, placebo-controlled trial of anticonvulsant prophylaxis in adults with newly diagnosed brain metastases. Proc Amer Soc Clin Oncol. 1994;13:176.
83.
Glantz MJ, Cole BF, Friedberg MH, et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology. 1996;46:985–91.PubMedCrossRef
84.
• de Oliveira J, Santana I, Caires I, Caires-Lima I, Miranda V, Protasio B, et al. Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus. J Neuro-Oncol. 2014;120:399–403. This sample of sequential publications represents, including meta-analyses, represents independent evaluations of the role of prophylactic anti-seizure drug therapy in brain tumor patients, all with similar conclusions. CrossRef
85.
Wu A, Trinh V, Suki D, Graham S, Forman A, Weinberg J, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013;118:873–83.PubMedPubMedCentralCrossRef
86.
Garbossa D, Panciani P, Angeleri R, Battaglia L, Tartara F, Ajello M, et al. A retrospective two-center study of antiepileptic prophylaxis in patients with surgically treated high-grade gliomas. Neurol India. 2013;61:131–7.PubMedCrossRef
87.
Ansari S, Bohnstedt B, Perkins S, Althouse S, Miller J. Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections. J Neuro-Oncol. 2014;118:117–22.CrossRef
88.
Lee Y, Kim T, Bae S, Kim Y, Han J, Yun C, et al. Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. CNS Drugs. 2013;27:753–9.
89.
Siomin V, Angelov L, Li L, Vogelbaum M. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neuro-Oncol. 2005;74:211–5.CrossRef
90.
Hildebrand J. Management of epileptic seizures. Curr Op Oncol. 2004;16:314–7.CrossRef
91.
Aguiar D, Pazo R, Duran I, Terrasa J, Arrivi A, Manzano H, et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neuro-Oncol. 2004;66:345–50.CrossRef
92.
Taberner-Bonastre M, Peralta-Munoz S, Boza F, Guma I, Padro J. Neutropenia secondary to exposure to levetiracetam. Tumori. 2015;101:e145–6.PubMed
93.
Bilgili S, Calka O, Karadag A, Burakgazi A. EMPACT syndrome. Cutan Ocular Toxicol. 2011;30:328–30.CrossRef
94.
Zachenhofer I, Donat M, Oberndorfer S, Roessler K. Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neuro-Oncol. 2011;101:101–6.CrossRef
95.
Kandil A, Dvorak T, Mignano J, Wu J, Zhu J. Multifocal Stevens-Johnson syndrome after concurrent phenytoin and cranial and thoracic radiation treatment, a case report. Radiat Oncol. 2010;5:49.PubMedPubMedCentralCrossRef
96.
Beswick T, Cohen J. Dose-related levetiracetam-induced reticulated drug eruption. J Drugs Dermatol. 2010;9:409–10.PubMed
97.
Metro G, Pino S, Pellegrini D, Sacerdoti G, Fabi A. Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis. Anticancer Res. 2007;27:1167–9.PubMed
98.
• Lee C, Lai H, Chiu A, Chan S, Hsiao L, Lee S. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neuro-Oncol. 2016;127:445–53. The paper represents an interesting and novel approach that investigates the effects of multiple conventional anti-seizure drugs on the cellular growth of malignant gliomas. CrossRef
99.
Gefroh-Grimes H, Gidal B. Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. Acta Scandinavica. 2016;133:4–16.
100.
Kerkhof M, Dielemans J, Van Breemen M, Zwinkels H, Walchenbach R, Taphoorn M, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro-Oncology. 2013;15:961–7.
101.
Happold C, Gorlia T, Chinot O, Gilbert M, Nabors L, Wick W, et al. Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol. 2016;34:731–9.PubMedPubMedCentralCrossRef
102.
Robe P, Martin D, Nguyen-Khac M, Artesi M, Deprez M, Albert A, et al. Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 2009;9:372–9.PubMedPubMedCentralCrossRef
103.
Grossman S, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27:4155–61.
104.
• Amar S, Fields G. Potential clinical implications of recent MMP inhibitor design strategies. Expert Rev Proteomics. 2015;12:445–7. Matrix metalloproteinases is an enzyme family that has critical roles in several normal and disease states, highlighted in this paper. PubMedPubMedCentralCrossRef
105.
Ikonomidou Chrysanthy. Matrix metalloproteinases and epileptogenesis. Mol Cell Pediatr. 2014;1:1–6.CrossRef
106.
Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes & Diseases. 2015;2:26–34.CrossRef
107.
Stellas D, Patsavoudi E. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anti Cancer Agents Med Chem. 2012;12:707–17.CrossRef
108.
Kranendijk M, Salomons GS, Gibson K, Van Schaftingen E, Jakobs C, Struys E. A lymphoblast model for IDH2 gain-of-function activity in D-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies. Biochim Biophys Acta. 1812;2011:1380–4.
109.
Valadez J, Grover V, Carter M, Calcuttc M, Abiria S, Lundberg C, et al. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation. Cancer Lett. 2013;328:297–306.
110.
Fathi A, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol. 2012;2012:469592.PubMedCrossRef
111.
112.
113.
Veech R, Chance B, Kashiwaya Y, Lardy H, Cahill G Jr. Ketone bodies, potential therapeutic uses. IUBMB Life. 2001;51:241–7.PubMedCrossRef
114.
115.
Seyfried TN, Mukherjee P. Targeting energy metabolism in brain cancer: review and hypothesis. Nutr Metab (Lond). 2005;2:30–8.CrossRef
116.
Zhou WP, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketongenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond). 2007;4:5.CrossRef
117.
Maurer G, Brucker D, Bahr O, Harter P, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315.
118.
Seyfreid TN, Kiebish MA, Marsh J, Shelton LM, Huysentruyt LC, Mukherjee P. Metabolic management of brain cancer. Biocheim Biophys Acta. 1807;2011:577–94.
119.
Seyfried TN. Cancer as a metabolic disease: on the origin management and prevention of cancer. INc, Hoboken, NJ: John Wiley and Sons; 2012.CrossRef
120.
121.
Mukherjee P, El-Abbadi M, Kasperzyk J, Ranes M, Seyfried T. Dietary restriction reduces angiogenesis and growth in an orthoptic mouse brain tumour model. Br J Cancer. 2002;86:1615–21.PubMedPubMedCentralCrossRef
122.
Mukherjee P, Abate L, Seyfried T. Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res. 2004;10:5622–9.PubMedCrossRef
123.
Shelton L, Huysentruyt C, Mukherjee P, Seyfried T. Calorie restriction as an anti-invasive therapy for malignant brain cancer in the VM mouse. ASN Neuro. 2010;2:e00038.PubMedPubMedCentralCrossRef
124.
Jiang YS, Wang FR. Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J Neruooncol. 2013;114:25–32.CrossRef
125.
Lee C, Raffaghello L, Brandhorst S, Safdie M, Bianchi G, Marin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124ra27.PubMedPubMedCentralCrossRef
126.
Scheck A, Abdelwahab M, Fenton K, Stafford P. The ketogenic diet for the treatment of glioma: insights from genetic profiling. Epilepsy Res. 2012;100:327–37.PubMedCrossRef
127.
• Woolf E, Scheck A. The ketogenic diet for treatment of malignant glioma. J Lipid Res. 2015;56:5–10. This paper reviews the effects of the ketogenic diet, a known therapy for refractory epilepsy, on malignant glioma progression. PubMedPubMedCentralCrossRef
128.
Abdelwahab M, Fenton K, Preul M, Rho J, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant gliomas. PLoS One. 2012;7:e36197.
129.
Klein P. Mid-Atlantic Epilepsy Center (personal communication, 2017).
130.
131.
• Rosenow F, Luders H. Presurgical evaluation of epilepsy. Brain. 2001;124:1683–700. This paper provides a thorough a review regarding the pre-surgical work-up in refractory epilepsy. PubMedCrossRef
132.
Winkler P. Extraoperative mapping. In: Duffau H, editor. Brain mapping: from neural basis of cognition to surgical applications. NY: Springer Wien. New York; 2011. p. 91–100.CrossRef
133.
Hamer H, Najm I, Mohamed A, Wyllie E. Interictal epileptiform discharges in temporal lobe epilepsy due to hippocampal sclerosis versus medial temporal lobe tumors. Epilepsia. 1999;40:1261–8.PubMedCrossRef
134.
Duffau H. Brain mapping in tumors: intraoperative or extraoperative. Epilepsia. 2013;54(Suppl 9):79–83.PubMedCrossRef
135.
Duffau H. The challenge to remove diffuse low grade gliomas while preserving brain functions. Acta Neurochir. 2012;154:569–74.PubMedCrossRef
136.
• Guenot M, Isnard J, Ryvlin P, FFischer C, Ostrowsky K, Mauguiere F, et al. Neruophysiological monitoring for epilepsy surgery: the Talairach SEEG method. Stereotact Funct Neurosurg. 2001;77:29–32. This paper provides a thorough a review regarding the pre-surgical work-up in refractory epilepsy.
137.
Munari C, Hoffmann D, Francione S, Kahane P, Tassi L, Lo Russo G, et al. Stereo-electro-encephalography methodology: advantages and limits. Acta Neurol Scand Suppl. 1994;152:56–67.
138.
Talairach J, Bancaud J. Stereotaxic approach to epilepsy: methodology of anatomo-functional stereotactic investigations. Prog Neurol Surg. 1973;5:297–354.CrossRef
139.
Hamer H, Morris H, Mascha E, Karafa M, Bingaman W, Bej M, et al. Complications of invasive video-EEG monitoring with subdural grid electrodes. Neurology. 2002;58:97–103.
140.
Onal C, Otsubo H, Araki T, Chitoku S, Ochi A, Weiss S, et al. Complications of invasive subdural grid monitoring in children with epilepsy. J Neurosurg. 2003;98:1017–26.
141.
Johnston J Jr, Mangano F, Ojemann J, Park T, Trevathan E, Smyth M. Complications of invasive subdrual electrode Monitorin at St. Louis Children’s Hospital, 1994-2005. J Neurosurg. 2006;105:343–7.PubMed
142.
Wong C, Birkett J, Byth K, Dexter M, Somerville E, Gill D, et al. Risk factors for complications during intracranial electrode recording in presurgical evaluation of drug resistant partial epilepsy. Acta Neurochir. 2009;151:37–50.
143.
Wellmer J, von der Groeben F, Klarmann U, Weber C, Elger C, Urbach H, et al. Risks and benefits of invasive epilepsy surgery workup with implanted subdural and depth electrodes. Epilepsia. 2012;53:1322–32.
144.
Bekelis K, Radwan T, Desai K, Moses Z, Thadani V, Jobst B, et al. Subdural interhemispheric grid electrodes for intracranial epilepsymonitoring: feasibility, safety, and utility: clinical article. J Neurosurg. 2012;117:1182–8.PubMedCrossRef
145.
Vale F, Pollock G, Dionisio J, Benbadis S, Tatum W. Outcome and complications of chronically implanted subdural electrodes for the treatment of medically resistant epilepsy. Clin Neurol Neurosurg. 2013;115:985–90.PubMedCrossRef
146.
Tellez-Zenteno J, Hernandez-Ronquillo L, Moien-Afshari F, Wiebe S. Surgical outcomes in lesional and non-lesional epilepsy: a systematic review and meta-analysis. Epilepsy Res. 2010;89:310–8.PubMedCrossRef
147.
Englot D, Berger M, Barbaro N, Chang E. Predictors of seizure freedom after resection of supratentorial low-grade gloiomas. A review J Neurosurg. 2011;115:240–4.
148.
Bulacio J, Jehi L, Wong C, Gonzalez-Martinez J, Kotagal P, Nair D, et al. Long-term seizure outcome after resective surgery in patients evaluated with intracranial electrodes. Epilepsia. 2012;53:1722–30.
149.
Ozlen F, Gunduz A, Asan Z, Tanriverdi T, Ozkara C, Yeni N, et al. Dysembrioplastic neuroepithelial tumors and gangliogliomas: clinical results of 52 patients. Acta Neurochir. 2010;152:1661–71.
150.
You G, Huang L, Yang P, Zhang W, Yan W, Wang Y, et al. Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patiens with low-grade gliomas. Eur J Neurol. 2012;19:298–306.
151.
Gump W, Skjei K, Karkare S. Seizure control after subtotal lesional resection. Neurosurg Focus. 2013;34:E1.PubMedCrossRef
152.
Englot D, Han S, Berger M, Barbaro N, Chang E. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012a;70:921–8.PubMedCrossRef
153.
Englot D, Berger M, Barbaro N, Chang E. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia. 2012b;53:51–7.PubMedCrossRef
154.
155.
156.
• Mittal S, Shah A, Barkmeier D, Loeb J. Systems biology of human epilepsy applied to patients with brain tumors. Epilepsia. 2013;54(Suppl 9):35–9. This paper provides an expalantion of the systems biology approach developed to study patients with tumor-related epilepsy who undergo brain surgery. PubMedCrossRef
157.
Beaumont T, Yao B, Shah A, Kapatos G, Loeb J. Layer-specific CREB target gene induction in human neocortical epilepsy. J Neurosci. 2012;32:14389–401.PubMedPubMedCentralCrossRef
158.
Lipovich L, Dachet F, Cai J, Bagla S, Balan K, Jia H, et al. Activity-dependent human brain coding/noncoding gene regulatory networks. Genetics. 2012;192:1133–48.
159.
Ruda R, Bello L, Duffau H, Soffietti R. Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro-Oncology. 2012;14:iv55–64.PubMedPubMedCentralCrossRef
Metadata
Title
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches
Author
Jeffrey M. Politsky
Publication date
01-09-2017
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 9/2017
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-017-0777-3

Other articles of this Issue 9/2017

Current Neurology and Neuroscience Reports 9/2017 Go to the issue

Stroke (H Diener, Section Editor)

Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal

Dementia (K Marder, Section Editor)

New Therapeutic Strategies for Lewy Body Dementias

Epilepsy (CW Bazil, Section Editor)

Psychogenic Non-Epileptic Seizures

Dementia (K Marder, Section Editor)

Emerging Diagnostic and Therapeutic Strategies for Tauopathies

Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

CLIPPERS

Stroke (H Diener, Section Editor)

Unresolved Issues in Thrombectomy